Introduction
============

Type 2 diabetes mellitus (DM) is defined as a metabolic disorder in which patients become hyperglycemic from defects in insulin secretion or action, as well as from the hyperglucagonemia that ensues ([@b1-etm-0-0-6449]). Diabetic nephropathy (DN) is one of the major chronic microvascular complications of DM ([@b2-etm-0-0-6449]), and occurs in 20--40% of all patients with type 2 DM ([@b2-etm-0-0-6449],[@b3-etm-0-0-6449]). DN is caused by rising blood glucose and hypertension, obesity, oxidative stress, and unmitigated inflammation. Repeated or chronic insult to the kidneys leads to irreversible fibrotic damage of the glomeruli (glomerulosclerosis) and kidney tubules (tubulointerstitial fibrosis), and ultimately leads to end-stage renal disease (ESRD) ([@b4-etm-0-0-6449]). Due to these potential complications, DN can also cause a significant financial burden. Therefore, early diagnosis and management are critical.

Diabetes with microalbuminuria (30 mg/day) is an early clinical sign of DN; this subsequently progresses to macroalbuminuria (\>300 mg/day) and a decline in glomerular filtration rate ([@b5-etm-0-0-6449]). Over the past 20 years, therapies have significantly progressed beyond those that primarily reduce glucose levels; however, these therapies are also associated with unwanted side effects, such as weight gain. More recently developed drug classes can effectively improve glycemia and promote weight neutrality or even weight loss ([@b6-etm-0-0-6449]). Dipeptidyl peptidase-4 (DPP-4) inhibitors belong to these more recent drug classes.

DPP-4 inhibitors are a class of oral antihyperglycemic treatments for type 2 diabetes. They include sitagliptin, saxagliptin, vildagliptin, linagliptin, and teneligliptin. Sitagliptin, the first DPP-4 inhibitor on the market, was approved in 2006 for patients with type 2 DM ([@b6-etm-0-0-6449]), and has been widely used for the treatment of both DM and its complications, particularly DN. A recent study showed that DPP-4 inhibition in conjunction with angiotensin II type 1 receptor blockade produced enhanced renoprotective effects in patients with DN ([@b7-etm-0-0-6449]). However, whether sitagliptin has renoprotective properties remains controversial. Hattori\'s ([@b8-etm-0-0-6449]) study suggested that sitagliptin reduces albuminuria, which is dependent on satisfactory control of blood sugar. However, other groups discount the presence of a significant relationship between the change in the UACR and HbA1c, and claim that sitagliptin reduces blood pressure by increasing sodium diuresis ([@b9-etm-0-0-6449]--[@b12-etm-0-0-6449]). Sitagliptin increases the level of glucagon-like polypeptide (GLP)-1, GLP-1 decreases salt intake and increases urinary salt excretion by directly inhibiting the Na^+^/H^+^ exchange at the proximal tubular cells ([@b11-etm-0-0-6449],[@b12-etm-0-0-6449]). The abovementioned studies did not measure sodium diuresis and the sample sizes of the sitagliptin-treated cohorts were too small to be generalized; for example, Hattori\'s ([@b8-etm-0-0-6449]) study included only 36 subjects. Furthermore, some investigations (such as that of Kawasaki *et al* ([@b9-etm-0-0-6449])) were non-randomized and uncontrolled observation studies. Thus, whether sitagliptin truly provides a benefit remains unconfirmed. To that end, we performed a systematic review of several randomized controlled trials (RCTs) to investigate the effect of sitagliptin in patients with type 2 diabetes that also had incipient nephropathy. Moreover, we deem that sitagliptin truly has renoprotective effect for patients with early-stage DN.

Materials and methods
=====================

### Search strategy

Electronic searches of the PubMed, OVID, Cochrane library, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases were performed independently by two investigators in September 2017. The search terms were: ('Sitagliptin phosphate' or 'sitagliptin' or 'sitagliptin phosphate monohydrate') and ('diabetic nephropathies' or 'diabetic nephropathy' or 'diabetic kidney diseases' or 'diabetic complications'). We filtered the publications by titles, abstracts and keywords, and assessed the full-text versions while employing our inclusion and exclusion criteria (described below). The publication languages were restricted to English and Chinese. All clinical studies except case reports were chosen for our analysis. The first reports\' bibliographies, as well as references from selected studies, were also searched for other relevant publications.

### Selection criteria

We collected all relevant articles focusing on the relationship between sitagliptin and renal function index. The inclusion criteria were as follows: i) RCTs that compared sitagliptin to a control group that received routine treatment, or to drugs other than DPP-4 inhibitors; ii) all participants were type 2 diabetes patients with incipient nephropathy, with persistent microalbuminuria (incipient DN) defined as a urinary albumin-to-creatinine ratio between 30 and 300 mg/g in two morning spot urine collections sustained over 12 weeks ([@b2-etm-0-0-6449]); iii) renal function outcomes were reported in the studies; and iv) the study duration was longer than eight weeks. The following exclusion criteria were applied: i) Articles that had no information on renal function or the biochemical index of type 2 DN; ii) case reports, letters, reviews, expert opinion, conference abstracts, editorials, and non-English and non-Chinese language papers; and iii) all articles using cell lines and/or *in vitro*/*ex vivo* studies.

### Data extraction

The qualified studies were reviewed by two investigators independently; differences in interpretation were resolved by consensus. The following information was recorded for each study: General data, patient information, test drug information, course of treatment, and outcome data. The two researchers identified the articles that satisfied the selection criteria. Data heterogeneity was assessed to determine whether the studies could be analyzed. Study characteristics and clinical examination data were generalized and are described in table format.

### Statistical analysis

Quantitative and qualitative analyses were performed on corrected data. The RevMan v.5.3 software was downloaded from the Cochrane collaboration website and used for meta-analysis. The clinical and methodological heterogeneity of the included studies were analyzed using the χ^2^ and I^2^ tests. The fixed-effects model was used when P\>0.1 and I^2^\<50%, and each study showed acceptable heterogeneity. In cases where P\<0.1 and I^2^\>50%, and the study showed essential heterogeneity, we performed subgroup or sensitivity analysis. However, when many confounding factors appeared in the studies, the random-effects model was chosen regardless of the P and I^2^ values, according to the Cochrane Handbook ([@b13-etm-0-0-6449]). The mean difference (MD) or standard mean difference (SMD) and 95% confidence intervals (CIs) were used to compare continuous variables; risk ratios and 95% CIs were used to compare dichotomous variables ([@b13-etm-0-0-6449]). Whenever heterogeneity was significant, we sought to identify its source using the study-by-study exclusion method. P\<0.05 was considered to indicate a statistically significant difference. Egger\'s test and funnel plots were used to detect publication bias.

### Assessments of quality of evidence

Two investigators independently assessed the risk of bias as recommended by the Cochrane Handbook for Systematic Reviews of Interventions ([@b13-etm-0-0-6449]). Disagreements were resolved by a third reviewer. The quality appraisal of the literature included: Random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Articles that had clearly described details and met or surpassed the quality criteria were defined as low risk; otherwise, they were deemed high-risk. Equivocal articles in terms of quality criteria were deemed to be of unclear risk.

Results
=======

### Study characteristics

We initially collected 85 articles from the PubMed, OVID, the Cochrane library, CNKI, and Wanfang databases. Thirty full-text studies were extracted for more detailed assessment, and were filtered via their titles and abstracts for final eligibility assessment. Ten crossover trials without control groups were excluded, as were seven trials that lacked renal function marker analysis. Eventually, 13 publications that satisfied the inclusion criteria were selected for this meta-analysis. The article search process and study selection are shown in [Fig. 1](#f1-etm-0-0-6449){ref-type="fig"}.

Of the total 942 patients included, 481 belonged to treatment groups, while 461 belonged to control groups receiving routine treatment such as controlled diet and exercise therapy, antihypertensive drugs, or other antihyperglycemic treatments excluding DPP-4 inhibitors. The treatment groups included sitagliptin combined with routine treatment, antihypertensive drugs, or other antihyperglycemic treatment. The doses of sitagliptin used in the included trials differed slightly. Sitagliptin intake was generally 100 mg per day; only one trial used 50 mg per day ([@b14-etm-0-0-6449]). Among the 13 trials, 12 adopted a two-armed parallel group design while one (Zhang *et al* ([@b15-etm-0-0-6449])) adopted a three-armed group design. The durations of interventions in the diabetes trials were different, ranging from eight to 24 weeks. Six studies lasted 24 weeks, one lasted eight weeks, and the remainder lasted 12 weeks. Basic information about the involved studies is shown in [Table I](#tI-etm-0-0-6449){ref-type="table"}.

### Risk of bias

The risk of bias assessments are shown in [Figs. 2](#f2-etm-0-0-6449){ref-type="fig"} and [3](#f3-etm-0-0-6449){ref-type="fig"}. All trials were randomly designed, but eight ([@b16-etm-0-0-6449]--[@b23-etm-0-0-6449]) were judged to have unclear risks of bias owing to allocation concealment.

Blinding of participants, personnel, and outcome assessors were not undertaken in three studies ([@b15-etm-0-0-6449],[@b21-etm-0-0-6449],[@b22-etm-0-0-6449]). Additionally, it was not clear whether the participants and personnel were blinded in eight trials ([@b16-etm-0-0-6449],[@b18-etm-0-0-6449]--[@b20-etm-0-0-6449],[@b23-etm-0-0-6449]--[@b26-etm-0-0-6449]). Furthermore, it was unclear if the outcome assessors were blinded in eight of the studies ([@b16-etm-0-0-6449]--[@b20-etm-0-0-6449],[@b23-etm-0-0-6449],[@b24-etm-0-0-6449],[@b26-etm-0-0-6449]). Attrition bias was ambiguous in eight of the trials ([@b15-etm-0-0-6449]--[@b18-etm-0-0-6449],[@b21-etm-0-0-6449]--[@b23-etm-0-0-6449],[@b26-etm-0-0-6449]); however, all trials showed a low risk of reporting bias or other biases.

Effect of interventions
-----------------------

### Effect on proteinuria and renal function

Five trials ([@b15-etm-0-0-6449],[@b20-etm-0-0-6449],[@b22-etm-0-0-6449],[@b24-etm-0-0-6449],[@b25-etm-0-0-6449]) investigated the effect of sitagliptin on quantitative 24-hour urinary total protein (UTP) test results ([Fig. 4A](#f4-etm-0-0-6449){ref-type="fig"}). The sitagliptin and control groups comprised 170 and 148 patients, respectively. No significant heterogeneity was found between the results (χ^2^=7.02; I^2^=43%, P=0.14); hence, a fixed-effect model was used for statistical analysis. The 24-h UTP was lower in the treatment group than in the control group (MD=−25.71, 95% CI-30.75 to −20.66, P\<0.00001). Three trials ([@b19-etm-0-0-6449]--[@b21-etm-0-0-6449]) were used to compare serum cystatin C (CysC) levels between the two groups ([Fig. 4B](#f4-etm-0-0-6449){ref-type="fig"}). The treatment group included 92 patients and the control group included 95 patients. No significant heterogeneity was found between the two groups (χ^2^=2.26; I^2^=11%, P=0.32). Patients receiving sitagliptin had better CysC levels than the control group (MD=−0.59, 95% CI-0.64 to-0.54, P\<0.00001). Three trials reported serum creatinine (SCr) levels ([@b20-etm-0-0-6449],[@b23-etm-0-0-6449],[@b25-etm-0-0-6449]) with 106 patients in each of the treatment and control groups. These trials showed homogeneity in the consistency of their results (χ^2^=1.00; I^2^=0%, P=0.61). Therefore, a fixed-effect model was selected for statistical analysis, which revealed no difference between the sitagliptin and control groups in terms of changes in SCr levels (MD=−1.07, 95% CI-3.52 to 1.37, P=0.39; [Fig. 4C](#f4-etm-0-0-6449){ref-type="fig"}). Overall, however, the results suggested that sitagliptin reduced proteinuria, thus ameliorating renal function.

### Effect on improving inflammation

Three trials ([@b17-etm-0-0-6449],[@b18-etm-0-0-6449],[@b24-etm-0-0-6449]) compared C-reactive protein (CRP) levels between the experimental and control groups (100 patients each); no significant heterogeneity was observed (χ^2^=0.47; I^2^=0%, P=0.79; [Fig. 5](#f5-etm-0-0-6449){ref-type="fig"}) and a fixed-effect model was used for statistical analysis. The sitagliptin group expressed lower CRP levels than the control group (MD=−0.81; 95% CI-1.20 to −0.42; P\<0.0001; [Fig. 5](#f5-etm-0-0-6449){ref-type="fig"}), indicating that sitagliptin exhibits anti-inflammatory effects in patients with DN.

### Effect on blood glucose and glycosylated hemoglobin

Eleven trials ([@b14-etm-0-0-6449],[@b16-etm-0-0-6449]--[@b21-etm-0-0-6449],[@b23-etm-0-0-6449]--[@b26-etm-0-0-6449]) investigated the effect of sitagliptin on fasting blood glucose (FBG) levels. The sitagliptin and control groups comprised 417 and 419 patients, respectively. The statistical heterogeneity of the FBG data was unacceptable (χ^2^=17.10; I^2^=42%, P=0.07); therefore, we used the random-effect model for meta-analysis. The pooled result showed no difference between the sitagliptin and control groups (SMD=−0.06; 95% CI −0.20 to 0.07; P=0.36; [Fig. 6A](#f6-etm-0-0-6449){ref-type="fig"}).

Four trials ([@b16-etm-0-0-6449],[@b19-etm-0-0-6449],[@b23-etm-0-0-6449],[@b25-etm-0-0-6449]) investigated the effect of sitagliptin on postprandial blood glucose (PBG) with 174 in each of the treatment and control groups; there was no significant heterogeneity (χ^2^=1.37; I^2^=0%, P=0.71) and a fixed-effect model was used. However, no differences in FBG between the two groups were detected (MD=−0.23; 95% CI-0.52 to 0.06; P=0.12; [Fig. 6B](#f6-etm-0-0-6449){ref-type="fig"}).

As shown in [Fig. 6C](#f6-etm-0-0-6449){ref-type="fig"}, 11 trials ([@b14-etm-0-0-6449],[@b16-etm-0-0-6449]--[@b23-etm-0-0-6449],[@b25-etm-0-0-6449],[@b26-etm-0-0-6449]) investigated the effect of sitagliptin on HbA1c; the heterogeneity was acceptable (χ^2^=14.03; I^2^=29%, P=0.17), and therefore the fixed-effect model was used. Sitagliptin did not influence HbA1c levels (MD=−0.04; 95% CI-0.10 to 0.03; P=0.30); hence, it is unclear if sitagliptin decreases blood glucose levels.

### Effect on blood lipids

Five trials ([@b20-etm-0-0-6449],[@b23-etm-0-0-6449]--[@b26-etm-0-0-6449]) investigated total cholesterol (TC) and triglyceride (TG) levels ([Fig. 7](#f7-etm-0-0-6449){ref-type="fig"}), with 170 subjects in the treatment group and 166 in the control group. There was no significant heterogeneity between the TC and TG results (TC: χ^2^=5.31, I^2^=25%, P=0.26; TG: χ^2^=5.93, I^2^=33%, P=0.20), so the fixed-effect model was used for meta-analysis. Sitagliptin treatment reduced the level of TC (MD=−0.13, 95% CI-0.22 to-0.03, P=0.009), but not TG (MD=−0.01, 95% CI-0.07 to 0.05, P=0.73; [Fig. 7](#f7-etm-0-0-6449){ref-type="fig"}). These data showed that sitagliptin does affect blood lipid levels.

### Adverse events

Only five trials ([@b15-etm-0-0-6449],[@b17-etm-0-0-6449],[@b21-etm-0-0-6449],[@b22-etm-0-0-6449],[@b25-etm-0-0-6449]) investigated adverse events, two of which ([@b17-etm-0-0-6449],[@b21-etm-0-0-6449]) reported no such occurrences. Of the remaining three trials, one ([@b25-etm-0-0-6449]) found that patients in the treatment group presented with hypoglycemia (n=2), dizziness (n=2), and gastrointestinal tract reaction (n=2); the same conditions were experienced in patients in their control groups (n=3, n=1, and n=2, respectively). Another trial ([@b15-etm-0-0-6449]) reported a slight cough (n=1) in the control group and gastrointestinal tract reaction (n=2) in the treatment group. The final trial ([@b22-etm-0-0-6449]) reported adverse effects without specifying their natures. However, there were no serious adverse events reported in any of these trials. The most common events were gastrointestinal tract reactions and hypoglycemia, but these symptoms resolved quickly.

### Evaluation of publication bias

In the present study, funnel plots were used to identify publication bias. Asymmetry is observed in [Fig. 8A and B](#f8-etm-0-0-6449){ref-type="fig"}; moreover, one study falls outside the 95% confidence interval ([Fig. 8A](#f8-etm-0-0-6449){ref-type="fig"}). Egger\'s test of FBG (P=0.164) and HbAlc (P=0.941) showed that there was no publication bias in the studies included ([Fig. 8A and B](#f8-etm-0-0-6449){ref-type="fig"}).

Discussion
==========

DN treatment aims to reduce proteinuria. Angiotensin II receptor blockers (ARBs) are widely used for the improvement of proteinuria in patients with DN, and provide more favorable outcomes especially in the incipient DN stage, as shown in the INNOVATION study ([@b27-etm-0-0-6449],[@b28-etm-0-0-6449]). However, ARBs cannot delay progression to ESRD, thus rendering renal replacement therapy inevitable. Therefore, determining whether sitagliptin exhibits a renoprotective effect is of great scientific value.

Our meta-analysis included 942 patients; most of the investigated trials adopted a randomized double-blind parallel control design. For assessing kidney function, 24-h UTP, CysC, and SCr were chosen as the ideal markers of kidney function because they are less influenced by age, sex, body mass, and inflammatory conditions ([@b29-etm-0-0-6449],[@b30-etm-0-0-6449]). Additionally, our data suggested that sitagliptin may have positive effects on lowering the 24-h UTP, CysC, and CRP. Although sitagliptin did not appear to affect SCr, it still offers the benefit of reducing proteinuria, ameliorating renal function, and producing an anti-inflammatory response in patients with DN.

Importantly, TGF-β~1~/Smad3 is known to mediate fibrosis in DN. A recent study found that sitagliptin prevented kidney injury, reduced albuminuria, and reduced inflammation by blocking the TGF-β~1~/Smad3 signaling pathway. Wang *et al* ([@b31-etm-0-0-6449]) reported that sitagliptin down-regulated the level of Smad3 phosphorylation by inhibiting TGF-β~1~, and up-regulated Smad7 protein expression to prevent the production of collagen IV and fibronectin and to reduce extracellular matrix accumulation. Their data inferred that sitagliptin performs anti-fibrosis and anti-inflammatory functions in the kidney.

With respect to blood glucose and lipid levels, sitagliptin was found to reduce TC level but appeared to have no effect on FBG, PBG, HbA1c, or TG. Hence, the role of sitagliptin in decreasing blood glucose levels remains unclear, which is inconsistent with prevailing viewpoints that sitagliptin reduces glucose levels, does not elicit weight gain, and decreases the risk of hypoglycemia ([@b32-etm-0-0-6449],[@b33-etm-0-0-6449]).

There are some possible reasons for the discrepancies found in the literature. First, the number of included articles regarding PBG and TG was less than 10, so the funnel plot could not evaluate the publication bias. Second, although there is no publication bias in FBG and HbA1c, as shown by Egger\'s test and asymmetry in the funnel plots, we believe that other biases may have existed in the included studies. Potential biases in the trials that could have led to incorrect conclusions regarding sitagliptin include non-disclosure of allocation concealment, incomplete outcome data, or double-blind analysis status. Only three of five trials that investigated adverse events mentioned these potential biases. As conclusions concerning safety could not be made in our meta-analysis, the safety of sitagliptin requires more rigorous investigations in future clinical trials.

Sitagliptin was shown to reduce proteinuria, ameliorate renal function, and produce an anti-inflammatory effect in patients with early DN. These findings can be useful for guidance in the clinical application of sitagliptin.
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###### 

Characteristics of the included studies.

  Stydy, year           Sample size   Testing scheme   Test group                     Control group     Duration (weeks)   Outcomes   (Refs.)
  --------------------- ------------- ---------------- ------------------------------ ----------------- ------------------ ---------- -----------------------
  Mori *et al*, 2014    41/44         RAN              SIT (50 mg qd) Plus RT         RT                24                 ACFGH      ([@b14-etm-0-0-6449])
  Zhang *et al*, 2016   29/29         UNK              SIT (100 mg qd) Plus IRB       IRB (150 mg qd)   12                 GI         ([@b15-etm-0-0-6449])
  Hu *et al*, 2016      80/80         RAN              SIT (100 mg qd) Plus RT        RT                12                 ABCH       ([@b16-etm-0-0-6449])
  Huang *et al*, 2016   30/30         RAN              SIT (100 mg qd) Plus GLI       GLI (30 mg qd)    12                 ABCGJ      ([@b17-etm-0-0-6449])
  Jin *et al*, 2016     40/40         RAN              SIT (100 mg qd) Plus RT        RT                24                 ACFJ       ([@b18-etm-0-0-6449])
  Lan *et al*, 2016     24/24         RAN              SIT (100 mg qd) Plus RT        RT                24                 ABCL       ([@b19-etm-0-0-6449])
  Yang *et al*, 2015    36/36         RAN              SIT (100 mg qd) Plus RT        RT                24                 ACDEILK    ([@b20-etm-0-0-6449])
  Ying *et al*, 2016    32/35         UNK              SIT (100 mg qd) Plus RT        RT                12                 ACL        ([@b21-etm-0-0-6449])
  Zhao *et al*, 2014    35/13         UNK              SIT (100 mg qd) Plus VAL       VAL (80 mg qd)    24                 CI         ([@b22-etm-0-0-6449])
  Huang *et al*, 2016   30/30         RAN              SIT (100 mg qd) Plus RT        RT                12                 ACDEFK     ([@b23-etm-0-0-6449])
  Wang *et al*, 2015    30/30         RAN              SIT (100 mg qd) Plus Insulin   INS               8                  ADEIJ      ([@b24-etm-0-0-6449])
  Han *et al*, 2015     40/40         RAN              SIT (100 mg qd) Plus GLI       GLI (30 mg qd)    12                 ABCDEFIK   ([@b25-etm-0-0-6449])
  Hao *et al*, 2015     34/30         RAN              SIT (100 mg qd) Plus RT        RT                24                 ACDEFGH    ([@b26-etm-0-0-6449])

RNA, randomized controlled trial; UNK, unknown; SIT, sitagliptin; RT, routine treatment; GLI, gliclazide; VAL, valsartan; IRB, irbesartan; INS, insulin; A, fasting blood glucose; B, postprandial blood glucose; C, glycosylated hemoglobin; D, total cholesterol; E, triglyceride; F, low density lipoprotein cholesterol; G, urine albumin-to-creatinine ratio; H, estimated glomerular filtration rate; I, 24-hour urinary protein quantitative; J, C-reactive protein; K, serum creatinine; L, serum cystatin C.
